740 related articles for article (PubMed ID: 35303871)
21. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
[TBL] [Abstract][Full Text] [Related]
22. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
Sterner RM; Cox MJ; Sakemura R; Kenderian SS
J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
[TBL] [Abstract][Full Text] [Related]
23. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
24. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
25. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
Front Immunol; 2022; 13():865424. PubMed ID: 35784280
[TBL] [Abstract][Full Text] [Related]
26. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
27. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
[TBL] [Abstract][Full Text] [Related]
29. Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
Wälchli S; Sioud M
Methods Mol Biol; 2020; 2115():407-417. PubMed ID: 32006413
[TBL] [Abstract][Full Text] [Related]
30. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
[TBL] [Abstract][Full Text] [Related]
31. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
[TBL] [Abstract][Full Text] [Related]
32. Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A; Rezvani K
Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
[TBL] [Abstract][Full Text] [Related]
33. A versatile system for rapid multiplex genome-edited CAR T cell generation.
Ren J; Zhang X; Liu X; Fang C; Jiang S; June CH; Zhao Y
Oncotarget; 2017 Mar; 8(10):17002-17011. PubMed ID: 28199983
[TBL] [Abstract][Full Text] [Related]
34. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.
Fix SM; Jazaeri AA; Hwu P
Cancer Discov; 2021 Mar; 11(3):560-574. PubMed ID: 33563662
[TBL] [Abstract][Full Text] [Related]
35. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
36. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
37. Release Assays and Potency Assays for CAR T-Cell Interventions.
Dias J; Cadiñanos-Garai A; Roddie C
Adv Exp Med Biol; 2023; 1420():117-137. PubMed ID: 37258787
[TBL] [Abstract][Full Text] [Related]
38. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
Ding R; Chao CC; Gao Q
Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy to get on point with base editing.
Harbottle JA
Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
[TBL] [Abstract][Full Text] [Related]
40. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
Quazi S
Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]